The estimated Net Worth of Eric J Loumeau is at least $3.95 Million dollars as of 16 February 2024. Mr. Loumeau owns over 5,000 units of AnaptysBio Inc stock worth over $293,344 and over the last 9 years he sold ANAB stock worth over $114,558. In addition, he makes $3,541,570 as Chief Operating Officer and General Counsel at AnaptysBio Inc.
Sign up
Mr. Loumeau ANAB stock SEC Form 4 insiders trading
Eric has made over 10 trades of the AnaptysBio Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of ANAB stock worth $70,100 on 16 February 2024.
The largest trade he's ever made was exercising 10,000 units of AnaptysBio Inc stock on 10 February 2021 worth over $140,200. On average, Eric trades about 1,486 units every 90 days since 2015. As of 16 February 2024 he still owns at least 8,240 units of AnaptysBio Inc stock.
You can see the complete history of Mr. Loumeau stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Eric Loumeau biography
Eric Joseph Loumeau serves as Chief Operating Officer, General Counsel of the Company. Mr. Loumeau will lead business strategy, operations and legal affairs at AnaptysBio. He joined AnaptysBio in August 2018 as General Counsel and has also served as Interim Chief Financial Officer since August 2019. Prior to AnaptysBio, Mr. Loumeau has served as General Counsel and Chief Compliance Officer at Otonomy, Chief Financial Officer of Rempex Pharmaceutics and General Counsel at Hollis-Eden Pharmaceuticals. Mr. Loumeau has also practiced securities and corporate law at multiple national law firms. Mr. Loumeau received his J.D. from Boalt Hall School of Law at the University of California, Berkeley, and his B.S. in Finance from Brigham Young University.
What is the salary of Eric Loumeau?
As the Chief Operating Officer and General Counsel of AnaptysBio Inc, the total compensation of Eric Loumeau at AnaptysBio Inc is $3,541,570. There are 1 executives at AnaptysBio Inc getting paid more, with Hamza Suria having the highest compensation of $7,875,190.
How old is Eric Loumeau?
Eric Loumeau is 57, he's been the Chief Operating Officer and General Counsel of AnaptysBio Inc since 2020. There are 7 older and 6 younger executives at AnaptysBio Inc. The oldest executive at AnaptysBio Inc is Hollings Renton, 73, who is the Lead Independent Director.
What's Eric Loumeau's mailing address?
Eric's mailing address filed with the SEC is 4796 Executive Dr, San Diego, CA 92121, USA.
Insiders trading at AnaptysBio Inc
Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1, and James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.
What does AnaptysBio Inc do?
founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c
What does AnaptysBio Inc's logo look like?
Complete history of Mr. Loumeau stock trades at AnaptysBio Inc and Otonomy Inc
AnaptysBio Inc executives and stock owners
AnaptysBio Inc executives and other stock owners filed with the SEC include:
-
Hamza Suria,
President, Chief Executive Officer, Director -
Eric Loumeau,
Chief Operating Officer, General Counsel -
Hamza Suria,
Pres, CEO & Director -
Dennis M. Mulroy,
Chief Financial Officer -
Dr. Paul F. Lizzul,
Chief Medical Officer -
James Topper,
Independent Chairman of the Board -
Dennis Fenton,
Independent Director -
Hollings Renton,
Lead Independent Director -
J. Anthony Ware,
Independent Director -
John Schmid,
Independent Director -
Laura Hamill,
Independent Director -
Paul Lizzul,
Chief Medical Officer -
Dennis Mulroy,
Chief Financial Officer -
Eric J. Loumeau,
COO & Gen. Counsel -
David McKeon,
VP & Controller -
Dr. Margaret Marino,
Sr. VP of Project Management -
Beth Mueller,
Sr. VP of HR -
Nicholas Lydon,
Director -
Carol Giltner Gallagher,
Director -
Matthew Moyle,
Chief Scientific Officer -
James A Schoeneck,
Director -
Dominic Piscitelli,
Chief Financial Officer -
Marco Londei,
Chief Medical Officer -
Healthcare Vii, L.P.Frazier...,
-
Healthcare V, Lpfhm V, Lpfh...,
-
Holdings A/S Novo,
10% owner -
Ventures Vii L Pavalon Vent...,
-
John A Orwin,
-
Magda Marquet,
-
Rita Jain,
-
Capital, Llcnodelman Oleg E...,
-
Capital, Llc Eco R1,
10% owner -
Daniel Faga,
CEO